## INDIAN PHARMACOPOEIA COMMISSION



## National Coordination Centre- Pharmacovigilance Programme of India (PvPI) MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401, Fax: 0120-2783311 e-mail: pvpi.ipc@gov.in, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2017-18/01

January 2017

## **Drug Safety Alerts**

The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.

## **Table**

Sl. No	Suspected Drugs	Indication	Adverse Reactions
1	Cefepime	For serious CRTI, uncomplicated and complicated UTI, Uncomplicated skin & skin structure, infection acute exacerbation of chronic bronchitis & intraabdominal infection.	Dermatitis Lichenoid
2	Losartan	Congestive heart failure, hypertension (myocardial infarction along with stroke including reduction of stroke risk in hypertension) with left ventricular hypertrophy, diabetic nephropathy in type II diabetes	Burning Micturation
3	Amisulpride	For acute and chronic schizophrenic disorders, in which positive symptoms and or negative symptoms are prominent, including patients characterised by predominant negative symptoms.	Tinnitus
4	Carbamazepine	Partial seizures with or without secondary generalisation, trigeminal neuralgia, bipolar disorder	Bruxism

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events associated with the use of above drugs. If such events are encountered please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in) or by PvPI Helpline No. 1800-180-3024.